RT Journal Article
SR Electronic
T1 Clinical validation of RCSMS: a rapid and sensitive CRISPR-Cas12a test for the molecular detection of SARS-CoV-2 from saliva
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.26.21256081
DO 10.1101/2021.04.26.21256081
A1 del Prado, Joaquín Abugattás Núñez
A1 Reyes, Angélica Quintana
A1 La Torre, Juan Blume
A1 Gutiérrez Loli, Renzo
A1 Pinzón Olejua, Alejandro
A1 Chamorro Chirinos, Elena Rocío
A1 Loza Mauricio, Félix Antonio
A1 Maguiña, Jorge L.
A1 Leon, Julio
A1 Rodríguez Aliaga, Piere
A1 Málaga Trillo, Edward
YR 2021
UL http://medrxiv.org/content/early/2021/04/29/2021.04.26.21256081.abstract
AB Early detection of SARS-CoV-2 using molecular techniques is paramount to the fight against COVID-19. Due to its high sensitivity and specificity, RT-qPCR is the “gold standard” method for this purpose. However, its technical requirements, processing time and elevated costs hamper its use towards massive and timely molecular testing for COVID-19 in rural and socioeconomically deprived areas of Latin America. The advent and rapid evolution of CRISPR-Cas technology has boosted the development of new pathogen detection methodologies. Recently, DETECTR -a combination of isothermal RT-LAMP amplification and Cas12a-mediated enzymatic detection-has been successfully validated in the Netherlands and the USA as a rapid and low-cost alternative to RT-qPCR for the detection of SARS-CoV-2 from nasopharyngeal swabs. Here, we evaluated the performance of RCSMS, a locally adapted variant of DETECTR, to ascertain the presence of SARS-CoV-2 in saliva samples from 276 patients in two hospitals in Lima, Perú (current status over a total of 350 samples). We show that a low-cost thermochemical treatment with TCEP/EDTA is sufficient to inactivate viral particles and cellular nucleases in saliva, eliminating the need to extract viral RNA with commercial kits, as well as the cumbersome nasopharyngeal swab procedure and the requirement of biosafety level 2 laboratories for molecular analyses. Our clinical validation shows that RCSMS detects up to 5 viral copies per reaction in 40 min, with sensitivity and specificity of 93.8% and 99.0% in the field, respectively, relative to RT-qPCR. Since CRISPR-Cas biosensors can be easily reprogrammed by using different guide RNA molecules, RCSMS has the potential to be quickly adapted for the detection of new SARS-CoV-2 variants. Notably, estimation of its negative and positive predictive values suggests that RCSMS can be confidently deployed in both high and low prevalence settings. Furthermore, our field study validates the use of lateral flow strips to easily visualize the presence of SARS-CoV-2, which paves the way to deploy RCSMS as a “point of care” test in environments with limited access to state-of-the-art diagnostic laboratories. In sum, RCSMS is a fast, efficient and inexpensive alternative to RT-qPCR for expanding COVID-19 testing capacity in low- and middle-income countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSince its beginning in May 2020, this project was supported mainly through generous private funding: ISA Rep, Minera Poderosa, SNMPE, SNP, Intercorp, Banco Pichincha, AC Farma, Industrias San Miguel, IBT Peru, Fuxion, Asociacion de Galleros del Peru. Other funding sources included CONCYTEC, the Spanish Agency for International Development Cooperation (AECID) and the Institute for Health Technology Assessment and Research (IETSI) - EsSalud.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Participants in the clinical validation stage were enrolled and sampled according to the ethics protocols approved by the INCOR EsSalud CEI (certificate 02/2021-CEI) and UPCH (SIDISI code 202099). All the participants provided their signed consent to provide samples for this study. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request https://drive.google.com/file/d/1yNYNYKWukbyAGIF2kK-jogDfUGn4xPT2/view